Because Patients Matter
Make Better-Informed Decisions
Be Ready Against Hereditary Cancer
Helping Children Lead Better Lives
MORE women with breast cancer could be spared chemotherapy if doctors switched to a new genetic test, research shows.
“EPclin (EndoPredict) Markedly Outperformed RS (Oncotype DX®) Across the 10-Year Follow-up Period” in a Large Head-to-Head Breast Cancer Study
Feb 11, 2016 | a GenomeWeb staff reporter
NEW YORK (GenomeWeb) – More young women with breast cancer are undergoing BRCA1 and BRCA2 mutation testing, according to a Dana-Farber Cancer Institute-led team of researchers.
Run For Hope is an annual run that aims to raise much-needed awareness and support for cancer research. For their 23rd year running, SciencewerkeDx was privileged to be a part of Run For Hope 2016 as a Gold Sponsor.
SAN ANTONIO, TX—EndoPredict (EP) provides more prognostic information than the Oncotype DX recurrence score (RS) for distant recurrence (DR) in overall, N+, and N– patient populations, with the greatest differences between EPclin and RS in patients who were N+. In addition, EPclin identified a group of patients at low risk who may be spared chemotherapy.
Cancer is a disease of abnormal gene function. Some gene changes that lead to cancer may be inherited. Breast, ovarian, prostate, and colon are some of these cancers that are linked to a family history. The genetic mutations that cause many of the known hereditary cancer syndromes have been identified, and genetic testing can confirm whether a condition is the result of an inherited syndrome. Genetic profiling may help you or other family members in planning health care for the future.
The majority of cardiovascular disease (CVD) is caused by risk factors that can be controlled, treated or modified. However, there are some major CVD risk factors that cannot be controlled. Current risk functions evaluate characteristics which can only be identified once they appear, without considering other potential factors such as the patient’s genetic constitution. Genetic profiling may provide personalized information, enabling cardiovascular risk to be identified in a more precise manner.
Nearly 1 in 5 individuals suffer from mental illness. There are over 270 medications containing warnings, precautions and dosage recommendations based on specific gene variants. Two thirds of patients will not achieve complete relief from their first medication.* Emerging science has allowed Genomind to develop a test designed to assist in the safe and appropriate selection of pharmacologic treatment for individuals who suffer from mental illness. Genomind’s leading mental health genetic test was designed to unlock unique insights for your clinician to more quickly identify a personalized treatment plan to help you avoid the painful process of treatment by trial and error *Depression Patients, Based on the STAR*D Trial
Rare genetic disorders can go undiagnosed for years. The lack of a diagnosis can have considerable adverse effects for patients and their families, including failure to identify potential treatments, failure to recognize risk of recurrence in subsequent pregnancies, and failure to provide anticipatory guidance and prognosis. Genetic testing has proven to be effective in detecting rare variants in an individual’s genome, offering hope to individuals with previously undiagnosed or untreated rare disorders.